ARTICLE | Clinical News
Arverapamil: Development discontinued
May 18, 2009 7:00 AM UTC
AGI said it would discontinue development of Rezular for IBS-D after top-line data from the double-blind, international Phase III ARDIS-1 trial in 711 patients showed that Rezular missed the primary e...